Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study

JAMA: The Journal of the American Medical Association

Volumn 260, Issue 5, 1988, Pages 641-651

  Manninen, Vesa ^a   Elo, M Olli ^a   Frick, M Heikki ^a   Haapa, Kauko ^a   Heinonen, Olli P ^a   Heinsalmi, Pertti ^a   Helo, Pekka ^a   Huttunen, Jussi K ^a   Kaitaniemi, Pertti ^a   Koskinen, Pekka ^a   Mäenpää, Hanna ^a   Mälkönen, Marjatta ^a   Mänttäri, Matti ^a   Norola, Seppo ^a   Pasternack, Amos ^a   Pikkarainen, Jarmo ^a   Romo, Matti ^a   Sjöblom, Tom ^a   Nikkilä, Esko A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL;

ADULT; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTILIPEMIC AGENTS; CORONARY DISEASE; DOUBLE-BLIND METHOD; FINLAND; GEMFIBROZIL; HUMAN; LIPIDS; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PENTANOIC ACIDS; RANDOM ALLOCATION; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; VALERATES;

EID: 0023726344     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1988.03410050061031     Document Type: Article

References (35)

1. Mänttäri M, Elo O, Frick MH, et al.: The Helsinki Heart Study: Basic design and randomization procedure. Eur Heart J 1987;8(suppl 1):1-29.
2. Frick MH, Elo 0, Haapa K, et al.: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
3. Mäenpää H, Javela K, Pikkarainen J, et al.: Minimal doses of digoxin: A new marker for compliance to medication. Eur Heart J 1987;8(suppl 1):31-37.
4. Mäenpää H, Manninen V, Heinonen OP: Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J 1987;8(suppl 1):39-43.
5. Kostner GM: Enzymatic determination of cholesterol in high-density lipoprotein fractions prepared by polyanion precipitation. Clin Chem 1976;22:695.
6. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
7. Fleiss JL: Statistical Methods for Rates and Proportions. New York, John Wiley & Sons Inc, 1973, pp 112-118.
8. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, John Wiley & Sons Inc, 1980.
9. Torstila I, Kaukola S, Manninen V, et al.: Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia. Acta Med Scand 1982;(suppl 668):123-129.
10. Dixon WJ: BMDP Statistical Software. Los Angeles, University of California Press, 1983, pp 576-594.
11. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
12. Oliver MF, Heady JA, Morris JN, et al.: A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate: Report from the Committee of Principal Investigators. Br Heart J 1978;40:1069-1118.
13. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
14. Manninen V, Mälkönen M, Eisalo A, et al.: Gemfibrozil in the treatment of dyslipidaemia: A five-year follow-up study. Acta Med Scand 1982;(suppl 668):82-87.
15. Gemfibrozil: A new lipid-lowering agent. Proc Roy Soc Med 1976;69(suppl 2):1-120.
16. Samuel P: Effects of gemfibrozil on serum lipids. Am J Med 1983;74:23-27.
17. Kesäniemi YA, Grundy SM: Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984;251:2241-2246.
18. Saku K, Gartside PS, Hynd BA, et al.: Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985;75:1702-1712.
19. Newton RS, Krause BR: Mechanisms of action of gemfibrozil: Comparison of studies in the rat to clinical efficacy, in Fears R (ed): International Telesymposium on Hyperlipidemia 1986: Pharmacological Control of Hyperlipidaemia. Barcelona, Spain, JR Prous Science Publishers, 1986, pp 171-186.
20. Kovanen PT, Koskinen P, Manninen V: A comparison of different formulations and dosage administrations of gemfibrozil. Am J Cardiol 1986;57:31G-34G.
21. Pasternack A, Vänttinen T, Solakivi T, et al.: Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987;27:163-168.
22. Sorisky A, Ooi TC, Simo IE, et al.: Change in composition of high density lipoprotein during gemfibrozil therapy. Atherosclerosis 1987;67:181-189.
23. Castelli WP, Garrison RJ, Wilson PWF, et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986;256:2835-2838.
24. Miller NE: Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987;113:589-597.
25. Pocock SJ, Shaper AG, Phillips AN, et al.: High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men. Br Med J 1986;292:515-519.
26. Carvalho ACA, Colman RW, Lees RS: Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia. Circulation 1974;50:570-574.
27. Laustiola K, Lassila R, Koskinen P, et al.: Gemfibrozil decreases platelet reactivity in hypercholesterolemic patients during physical stress. Clin Pharm Ther 1988;43:302-307.
28. Gordon DJ, Knoke J, Probstfield JL, et al.: High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 1986;74:1217-1225.
29. Levy RI, Brensike JF, Epstein SE, et al.: The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:325-337.
30. Tatami R, Mabuchi H, Ueda K, et al.: Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 1981;64:1174-1184.
31. Krauss RM: Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J 1987;113:578-582.
32. O’Brien JR, Etherington MD, Shuttleworth RD, et al.: A pilot study of the effect of gemfibrozil on some haematological parameters. Thromb Res 1982;26:275-279.
33. Wilhelmsen L, Svärsudd K, Korsan-Bengtsen K, et al.: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-505.
34. Markowe HLJ, Marmot MG, Shipley MJ, et al.: Fibrinogen: A possible link between social class and coronary heart disease. Br Med J 1985;291:1312-1314.
35. Kannel WB, Wolf PA, Castelli WP, et al.: Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987;258:1183-1186.